Meeting
2021 ASCO Annual Meeting
A phase 3, randomized, double-blind, placebo-controlled study of ruxolitinib plus parsaclisib in patients with JAK- and PI3K-inhibitor treatment-naïve myelofibrosis.
Authors
Abdulraheem Yacoub
University of Kansas Medical Center, Westwood Campus, Westwood, KS
Abdulraheem Yacoub , Susan Erickson-Viitanen , Feng Zhou , Albert Assad
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Myeloproliferative Neoplasms (MPN) and Mast Cell Disorders
Clinical Trial Registration Number
NCT04551066
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS7058)
DOI
10.1200/JCO.2021.39.15_suppl.TPS7058
Abstract #
TPS7058
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A randomized, double-blind, phase 3 study of jaktinib versus hydroxyurea (HU) in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF).
First Author: Yi Zhang
Poster
2015 ASCO Annual Meeting
Phase III randomized, double-blind, active-controlled study of momelotinib versus ruxolitinib in patients with myelofibrosis.
First Author: Elliott F. Winton
Poster
2021 ASCO Annual Meeting
Safety assessment of niraparib individualized starting dose in patients with platinum-sensitive recurrent ovarian cancer: A randomized, double-blind, placebo-controlled, phase III NORA trial.
First Author: Jing Wang
Poster
2023 ASCO Annual Meeting
SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.
First Author: Mark Andrew Dickson